Patent intelligence · US
US 11351183
Use of thyroid beta-agonists
Use of thyroid beta-agonists
Patent details — US 11351183
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 7, 2022
- Expiration
- Jun 2, 2042
- Applicant
- Viking Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/662, A61K31/665, A61P
Quick answer
US 11351183 (Use of thyroid beta-agonists) is held by Viking Therapeutics, Inc.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Viking Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/662, A61K31/665, A61P, A61P25/00, A61P25/28
More from Viking Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421282
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12318426
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12102646
Compositions for the treatment of fibrosis and inflammation
granted -
US 12083184
Hydrogel prodrug for treatment
granted -
US 11951114
Use of thyroid beta-agonists
granted -
US 11752217
Hydrogel prodrug for treatment
granted -
US 11744873
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 11707472
Compositions for the treatment of fibrosis
granted
Related coverage
Frequently asked questions
What is US patent 11351183?
US 11351183 (Use of thyroid beta-agonists) is held by Viking Therapeutics, Inc.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11351183?
Viking Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 11351183 expire?
Our index shows an expiration date of Jun 2, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.